About: Severe acute respiratory SARS-CoV-2 infection in dialysis patients in northern Italy: a single-centre experience

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Severe acute respiratory SARS-CoV-2 infection in dialysis patients in northern Italy: a single-centre experience Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	Severe acute respiratory SARS-CoV-2 infection in dialysis patients in northern Italy: a single-centre experience
Creator	Alfano, Gaetano Cappelli, Gianni Fontana, Francesco Magistroni, Riccardo Mori, Giacomo Lucchi, Leonardo Frisina, Monica Giaroni, Francesco
source	Medline; PMC
abstract	BACKGROUND: Dialysis patients are considered at high risk for COVID-19 and the infection can easily spread in dialysis units. METHODS: We conducted an observational single-centre cohort study to describe clinical characteristics, treatments and outcomes of dialysis patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. We tested patients who presented symptoms or had contact with a confirmed case. We enrolled 15 patients positive for SARS-CoV-2. RESULTS: We tested 37 of 306 dialysis patients. Patients with SARS-CoV-2 infection were older (mean age 75.96 ± 11.09 years) and all had comorbidities. At presentation, most had interstitial infiltrates on chest X-ray, three-quarters had leucopenia and none had respiratory insufficiency. During follow-up, there was an increase in serum C-reactive protein and interleukin-6. Eighty percent of patients received supplemental oxygen; none received non-invasive ventilation, one was intubated. Most patients (80%) were treated with oral hydroxychloroquine for a median time of 6.5 days [interquartile range (IQR) 5–14.5] and 40% received azithromycin; two patients received a short course of antivirals and one received a single dose of tocilizumab. Only two patients did not require hospitalization. Of the nine survivors, eight still tested positive for SARS-CoV-2 a median of 19 days (IQR 9.25–23) after diagnosis. Six patients died (case fatality rate 40%) a median of 5.5 days (IQR 1.75–9.75) after diagnosis. The main reported cause of death was respiratory failure related to COVID-19 (five patients). CONCLUSIONS: We report a single-centre experience of SARS-CoV-2 infection in dialysis patients. The disease showed a high case fatality rate and most patients required hospitalization. Survivors show prolonged viral shedding.
has issue date	2020-06-22(xsd:dateTime)
bibo:doi	10.1093/ckj/sfaa084
bibo:pmid	32695323
has license	cc-by-nc
sha1sum (hex)	7a31ddb21f030e8fc0ab7e0ac1574d371ec5dd2f
schema:url	https://doi.org/10.1093/ckj/sfaa084
resource representing a document's title	Severe acute respiratory SARS-CoV-2 infection in dialysis patients in northern Italy: a single-centre experience
has PubMed Central identifier	PMC7337639
has PubMed identifier	32695323
schema:publication	Clin Kidney J
resource representing a document's body	covid:7a31ddb21f030e8fc0ab7e0ac1574d371ec5dd2f#body_text
is schema:about of	named entity 'COVID-19' named entity 'DIALYSIS UNITS' named entity 'CONSIDERED' covid:arg/7a31ddb21f030e8fc0ab7e0ac1574d371ec5dd2f named entity 'Background' named entity 'dialysis' named entity 'COVID' named entity 'dialysis' named entity 'China' named entity 'case series' named entity 'symptoms and signs' named entity 'dialysis' named entity 'SARS-CoV-2' named entity '5.5' named entity 'dialysis' named entity 'chronic kidney disease' named entity 'assay' named entity 'dialysis' named entity 'diabetes' named entity 'tested positive' named entity 'COVID' named entity 'infection' named entity 'COVID' named entity 'SARS-CoV-2' named entity 'advance care planning' named entity 'case fatality rate' named entity 'infection' named entity 'off-label' named entity 'respiratory insufficiency' named entity 'epidemic' named entity 'infection' named entity 'CRP' named entity 'follow-up' named entity 'darunavir' named entity 'standard treatment' named entity 'dialysis' named entity 'intubated' named entity 'triage' named entity 'infection' named entity 'clinical indication' named entity 'cardiac ischaemia' named entity 'comorbidities' named entity 'diabetes' named entity 'cardiovascular disease' named entity 'IL-6' named entity 'informed consent' named entity 'chest X-ray' named entity 'COVID-19' named entity 'synergistic effect' named entity 'infection' named entity 'dialysis' named entity 'hypertension' named entity 'high levels' named entity 'SARS-CoV-2' named entity 'epidemic' named entity 'subcutaneous' named entity 'respiratory distress' named entity 'polymerase chain reaction' named entity 'kidney function' named entity 'demographic' named entity 'statistical significance' named entity 'demographic' named entity 'standard deviation' named entity 'HCQ' named entity 'viral shedding' named entity 'diagnostic procedure' named entity 'clinical characteristics' named entity 'asymptomatic' named entity 'first-line' named entity 'competitively inhibits' named entity 'dialysis' named entity 'Wuhan' named entity 'cardiovascular' named entity 'pharmacy'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software